From: Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease
Pt No. | G | Age | DFV(d) | Inappropriate initial CS treatment>2wa | IBCV (OD) | IBCV (OS) | IMTs and initial daily doses | RAU | ME | MA | Cataract/ IOL | MI | SRFRS | FBCV (OD) | FBCV (OS) | DFU (m) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 23 | 5 | – | 20/80 | 20/100 | CsA (200 mg/d) + AZA (100 mg/d) | + | + | – | + | OS | – | 20/25 | 20/80 | 40 |
2 | M | 28 | 22 | Insufficient dosing | 20/2000 | 20/2000 | CsA (200 mg/d) | + | + | – | + | OD | – | 20/1000 | 20/16 | 24 |
3 | M | 52 | 27 | Over-rapid tapering | 20/100 | 20/330 | CTX (100 mg/d) /CsA (200 mg/d) | + | + | + | + | OU | – | 20/33 | 20/16 | 43 |
4 | F | 50 | 20 | Insufficient dosing | 20/2000 | 20/400 | CTX (100 mg/d) | + | + | – | + | OU | – | 20/133 | 20/100 | 61 |
5 | M | 42 | 60 | Over-rapid tapering | 20/660 | 20/400 | CsA (200 mg/d) | + | + | + | + | OU | OD | 20/200 | 20/200 | 25 |
6 | M | 31 | 28 | Over-rapid tapering | 20/2000 | 20/2000 | CsA (200 mg/d) | + | – | + | + | OU | OU | 20/250 | 20/50 | 42 |
7 | F | 55 | 37 | Over-rapid tapering | 20/100 | 20/660 | CsA (150 mg/d) | + | + | + | – | OU | OS | 20/80 | 20/100 | 57 |
8 | F | 58 | 20 | Insufficient dosing | 20/660 | 20/660 | CsA (150 mg/d) | + | + | + | + | – | – | 20/25 | 20/25 | 24 |
9 | F | 36 | 35 | Over-rapid tapering | 20/2000 | 20/2000 | CsA (150 mg/d) | + | – | – | – | – | – | 20/20 | 20/20 | 24 |
10 | M | 25 | 50 | Over-rapid tapering | 20/2000 | 20/2000 | CsA (200 mg/d) | + | – | – | – | – | – | 20/16 | 20/20 | 13 |